Document is current
Any future updates will be listed below
-
Authors
Kehl, Kenneth L. http://orcid.org/0000-0001-5339-9797
Xu, Wenxin http://orcid.org/0000-0002-8450-2037
Gusev, Alexander http://orcid.org/0000-0002-7980-4620
Bakouny, Ziad
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Riaz, Irbaz Bin
Elmarakeby, Haitham
Van Allen, Eliezer M. http://orcid.org/0000-0002-0201-4444
Schrag, Deborah
-
Funding
Funding for this research was provided by:
Doris Duke Charitable Foundation (2020080)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA245899, 2P50CA101942-16, 5P30CA006516-56)
American Association for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Kohlberg Chair at Harvard Medical School Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research, Dana-Farber Cancer Institute
- License Information
-
More Information
Article History
Received: 14 September 2021
Accepted: 16 November 2021
First Online: 15 December 2021
Competing interests
: Dr. Kehl reports serving as a consultant/advisor to Aetion, receiving funding from the American Association for Cancer Research related to this work, and receiving honoraria from Roche and IBM. Dr. Schrag reports compensation from JAMA for serving as an Associate Editor and from Pfizer for giving a talk at a symposium. She has received research funding from the American Association for Cancer Research related to this work and research funding from GRAIL for serving as the site-PI of a clinical trial. Unrelated to this work, Dr. Choueiri reports serving on research/advisory boards and receiving honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive and others). Dr. Van Allen reports serving in advisory/consulting roles to Tango Therpeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, and Monte Rosa; receiving research support from Novartis and BMS; holding equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, and Monte Rosa; and receiving travel reimbursement from Roche/Genentech. The remaining authors declare no competing interests.
